Lundbeck appoints new chief commercial officer

Jacob Tolstrup, who has been an executive at the firm since 2012, will start in the role in the new year.

Jacob Tolstrup has been at Lundbeck for over 20 years. | Photo: PR

From the start of next year onwards, Jacob Tolstrup will lead Lundbeck's sales and marketing activities across all of the pharmaceutical company's business areas when he takes on the role of chief commercial officer (CCO), the company reveals in a press release.

Peter Anastasiou, executive vice president for North America, has decided to leave the post at the end of the year to pursue another opportunity, the press release reports, meaning that Tolstrup can take on this market alongside the markets in the rest of the world, which he is already responsible for. Anastasiou has been the person responsible for the launch of migraine drug Vyepti.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs